​In a Supreme Court Amicus Brief, A Coalition of leading Conservative Organizations in the US Challenges FDA on Abortion Drug Regulations

The Global Liberty Alliance, alongside Advancing American Freedom and over thirty other conservative groups, has taken a stand against the Food and Drug Administration's (FDA) recent actions concerning mifepristone, a widely used abortion medication. The coalition has filed an amicus brief highlighting concerns over the FDA's relaxation of safety protocols and questioning the approval standards of the drug.

Advancing American Freedom, leading the charge, asserts that the FDA's modifications to mifepristone's regulatory requirements significantly depart from the agency's commitment to upholding high safety standards. The coalition's challenge is rooted in concerns over the potential risks associated with the drug's use, mainly when administered without adequate medical supervision.

Mifepristone, approved by the FDA over two decades ago, is part of a two-drug regimen used for medication abortions. Recently, the FDA has made regulatory changes that have loosened the safety protocols surrounding its distribution and use, sparking a debate over patient safety and the integrity of the drug approval process.
The amicus brief argues against the FDA's approval and regulation processes for the abortion drug.

The coalition critiques the FDA's initial approval of mifepristone, claiming it overlooked significant safety concerns and asserting that the drug's approval and subsequent regulatory relaxations were politically motivated rather than based on solid scientific evidence. The coalition contends that pregnancy is not a condition that relevant federal regulations were intended to address, challenges the claim that mifepristone provides a meaningful therapeutic benefit over surgical abortion, and argues that approval was not based on adequate and well-controlled studies.

The brief also highlights concerns about the safety of chemical abortions, particularly considering lax reporting requirements and the removal of safeguards. The coalition argues that the FDA's decision to peel back these safety measures, including the requirement for in-person dispensing, endangers women's health and undermines the regulatory framework designed to ensure the safety and efficacy of pharmaceuticals.

​By filing the amicus brief, these organizations are calling for a reassessment of the FDA's actions and advocating for the reinstatement of stricter safety measures.